Methods of suppressing microglial activation

Details Methods of suppressing microglial activation Methods of suppressing microglial activation

2008-01-15

2008-01-15

Spector, Lorraine (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S021800, C530S300000, C530S326000

Reexamination Certificate

active

11091336

ABSTRACT:
Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. Also described are methods of screening compounds for the ability to suppress or reduce microglial activation.

REFERENCES:
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 5017566 (1991-05-01), Bodor
patent: 5168045 (1992-12-01), Dyer et al.
patent: 5182364 (1993-01-01), Dyer et al.
patent: 5204327 (1993-04-01), Kiyota et al.
patent: 5473039 (1995-12-01), Dyer et al.
patent: 5604198 (1997-02-01), Poduslo et al.
patent: 5686416 (1997-11-01), Kozarich et al.
patent: 6245751 (2001-06-01), Crutcher et al.
patent: 6605588 (2003-08-01), Lees et al.
patent: WO 92/10512 (1992-06-01), None
patent: WO 95/06456 (1995-03-01), None
patent: WO 97/14437 (1997-04-01), None
patent: WO 98/01101 (1998-01-01), None
patent: WO 99/08701 (1999-02-01), None
patent: WO 99/45950 (1999-09-01), None
patent: WO 2003/026479 (2003-04-01), None
patent: WO 2003/026479 (2003-04-01), None
Laskowitz et al., “Downregulation of Microglial Activation by Apolipoprotein E and ApoE-Mimetic Peptide”, Experimental Neurology, 167:74-85 (2001).
Yan et al., “Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors”, Science, 290:523-527 (2000).
Voet et al., Biochemistry, John Wiley & Sons, Inc., 126-128 and 228-234 (1990).
Mickle, J.E. et al., “Genotype-phenotype relationships in cystic fibrosis”, Med. Clin. North Am., 84(3):597-607 (May 2000).
A. Cardin et al., “Inhibition of Lymphocyte Proliferation b Synthetic Peptides Homologous to Human Plasma Apolipoproteins B and E” Biochemical and Biophysical Research Communications, 154:741-745 (Jul. 1998).
A. Lalazar et al., “Site-specific Mutagenesis of Human Apolipoprotein E”, The Journal of Biological Chemistry, 263:3542-3545 (1988).
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions”, Science, 247:1306-1310 (1990).
C. Dyer et al., “A Synthetic Peptide Mimic of Plasma Apolipoprotein E That Binds the LDL Receptor”, the Journal of Biological Chemistry, 266:22803-22806 (Dec. 1991).
C. Dyer et al., “Only Multimers of a Synthetic Peptide of Human Apolipoprotein E Are Biologically Active”, The Journal of Biological Chemsitry, 266:15009-15015 (1991).
Christie et al., “Expression of the Very Low-Density Lipoprotein Receptor (VLDL-r), an Apolipoprotein-E Receptor, in the Central Nervous System and in Alzheimer's Disease”, Journal of Neuropathology and Experimental Neurolog, 55(4):491-498 (1996).
D. Laskowitz et al., “Apolipotrotein E Suppresses Glial Cell Secretion of TNF-α”, Journal of Neuroimmunology, 76:70-74 (1997).
D. Laskowitz et al., “Apolipoprotein E-Deficient Mice Have Increased Susceptibility to Focal Cerebral Ischemia”, Journal of Cerebral Flow and Metabolism, 17:753-758 (1997).
Holtzman et al., “Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line”, Proc. Natl. Acad. Sci. USA, 92:9480-9484 (1995).
International Search Report for PCT/US99/05221 (mailed Nov. 3, 1999).
K. Crutcher et al., “Neurite Degeneration Elicited by Apolipoprotein E Peptides”, Experimental Neurology, 130:120-126 (1994).
K. Weisgraber et al., “The Receptor-binding Domain of Human Apolipoprotein E”, Journal of Biological Chemistry, 258:12348-12354 (1983).
L. Dong et al., “Enhanced Binding Activity of an Apolipoprotein E. Mutant, APO E5 to LDL Receptors on Human Fibroblasts”, Biochemical and Biophysical Research Communications, 168:409-414 (Apr. 1990).
L. Dong et al., “Site-Directed Mutagenesis of an Apolipoprotein E. Mutant, APO E5 (GLU3→LYS) and its Binding to Low Density Lipoprotein Receptors”, Biochemical and Biophysical Research Communications, 187:1180-1186 (Sep. 1992).
Laskowitz et al., “Apolipoprotein E and the CNS Response to Injury”, J. Cereb. Blood Flow Metab., 18(5):465-471 (1998).
Laskowitz et al., “Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production”, Clinical Neuroscience and Neuropathology, NeuroReport, 9(4):615-618 (1998).
M. Clay et al., “Localization of a Domain in Apolipoprotein E with Both Cytostatic and Cytotoxic Activity”, Biochemistry, 34:11142-11151 (1995).
Pardridge, W.M., “Chapter 12: Blood-brain barrier peptide transport and peptide delivery to the brain, Peptide-based drug design”, Ed. Taylor et al., American Chemical Society, 265-296 (1995).
R. Mrak et al., “Glial Cytokines in Alzheimer's Disease: Review and Pathogenic Implications”, Hum. Pathol., 26:816-823 (Aug. 1995).
S. Barger et al., “Microglial Activation by Alzheimer Amyloid Precursor Protein and Modulation by Apolipoprotein E”, Nature, 388:878-881 (Aug. 1997).
T. Innerarity et al., “Binding of Arginine-rich (E) Apoprotein after Recombination with Phospholipid Vesicles to the Low Density Lipoprotein Receptors of Fibroblast”, The Journal of Biological Chemistry, 254:4186-4190 (1979).
Vitek et al., “Modulation of Nitric Oxide Production in Human Macrophages by Apolipoprotein-E and Amyloid-Beta Peptide”, Biochemical and Biophysical Research Communications, 240-391 (1997).
Zielasek et al., Advances in Neuroimmunology, 6(2):191-22 (1996).
Misra et al., “Apolipoprotein E and Mimetic Peptide Initiate A Calcium-dependent Signaling Response in Macrophages”, Jour. Leukocyte Bio., 70:677-683 (2001).
Aono et al., “Protective Effects of Peptides Corresponding to the Receptor Binding Region of Apolipoprotein E on NMDA Excitotoxicity in Primary Neuronol-Glial Cultures”, Trip Report: 31st Annual Meeting of the Society for Neuroscience, San Diego, California (Nov. 10-15, 2001).
Benazzouz, A., et al., “Riluzole Prevents MPTP-induced Parkinsonism in the Rhesus Monkey: A Pilot Study,”Eur. J. Pharmacol. 284:299-307 (1995).
Champe et al., “IV. Tertiary Structure of Globular Proteins,” “V. Quaternary Structure of Proteins,” “VI Denaturation of Proteins,” and “VII. Protein Misfolding,” pp. 18-21 inLippincott's Illustrated Reviews: Biochemistry, 3rd Ed. Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, USA (2005).
Chen et al., “Motor and Cognitive Deficits in Apolipoprotein E Deficient Mice After Closed Head Injury,”Neuroscience80:1255-1262 (1997).
Gordon, I., et al., “Derangement in Stress Response of Apolipoprotein E-deficient Mice,”Neuroscience Letters206:212-214 (1996).
Jordan et al., “Isoform-Specific Effect of Apolipoprotein E on Cell Survival and β-Amyloid-induced Toxicity in Rat Hippocampal Pyramidal Neuronal Cultures,”J. Neurosci. 18:195-204 (1998).
Marzolo, M., et al., “Expression of α2-Macroglobulin Receptor/ Low Density Lipoprotein Receptor-Related Protein (LRP) in Rat Microglial Cells,”J. Neurosci. Res. 60:401-411 (2000).
Tolar, M., et al., “Truncated Apolipoprotein E (ApoE) Causes Increased Intracellualr Calcium and May Mediate ApoE Neurotoxicity,”J. Neuroscience19(16): 7100-7110 (1999).
Ludwig, “Supplementary European Search Report,” 3 pages, from EP Appl. No. 02775888.7, European Patent Office, Munich, Germany (mailed Mar. 9, 2007).

Affiliated with

Also associated with

Rating

Methods of suppressing microglial activation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of suppressing microglial activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of suppressing microglial activation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3906237